COMP <GO>
PRGO vs MRVI // EV/EBITDA & P/E VALUATION
Perrigo Company plc (NYSE) VS. Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: PRGO 10
— MRVI 1
■ METRIC PARITY
LAST: $15.90 (-0.13%) • MKT CAP: $2.21B
valuation
—
LAST: $8.46 (-0.47%) • MKT CAP: $2.20B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRGO VS. MRVI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRGO | MRVI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.10% | 18.30% | +16.80 | PRGO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.60% | -35.00% | +21.40 | PRGO | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.58% | -3.22% | +9.80 | PRGO | /fcf-yield <GO> |
| Operating Margin | -26.40% | -60.00% | +33.60 | PRGO | /operating-margins <GO> |
| Net Profit Margin | -33.50% | -60.00% | +26.50 | PRGO | /net-margins <GO> |
| Revenue Growth (YoY) | -2.80% | -28.30% | +25.50 | PRGO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 7.22% | 0.00% | +7.22 | PRGO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.04 | -2.84 | MRVI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 3/9 | +2.00 | PRGO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.3 | 53.6 | +1.69 | PRGO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.21B | $2.20B | $9.6M | PRGO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRGO REV | MRVI REV | PRGO GROSS % | MRVI GROSS % | PRGO FCF | MRVI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.25B | $185.7M | 35.1% | 18.3% | $145.1M | -$70.7M |
| FY 2024 | $4.37B | $259.2M | 35.3% | 41.8% | $244.6M | -$22.2M |
| FY 2023 | $4.66B | $288.9M | — | — | $405.5M | $126.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRGO // BETA —
MRVI // BETA —